Tilray Inc (TLRY) Receives $128.53 Consensus PT from Analysts
Shares of Tilray Inc (NASDAQ:TLRY) have earned an average rating of “Hold” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $128.53.
A number of equities analysts have issued reports on TLRY shares. Zacks Investment Research raised shares of Tilray from a “sell” rating to a “hold” rating in a research note on Saturday, January 5th. Roth Capital raised shares of Tilray from a “neutral” rating to a “buy” rating in a research note on Wednesday, February 20th. Piper Jaffray Companies began coverage on shares of Tilray in a research note on Wednesday, January 9th. They issued an “overweight” rating and a $90.00 price objective on the stock. Jefferies Financial Group began coverage on shares of Tilray in a research report on Friday, March 8th. They set an “underperform” rating and a $61.00 price target on the stock. Finally, Vertical Research began coverage on shares of Tilray in a research report on Friday, April 12th. They set a “sell” rating on the stock.
Shares of TLRY stock opened at $48.97 on Friday. Tilray has a 52-week low of $20.10 and a 52-week high of $300.00. The company has a market capitalization of $4.74 billion and a price-to-earnings ratio of -59.72. The company has a current ratio of 21.37, a quick ratio of 20.75 and a debt-to-equity ratio of 2.17.
In other news, CRO Edward Wood Pastorius, Jr. sold 46,557 shares of Tilray stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $63.38, for a total transaction of $2,950,782.66. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Brendan Kennedy sold 149,916 shares of Tilray stock in a transaction on Thursday, January 24th. The stock was sold at an average price of $74.21, for a total transaction of $11,125,266.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 396,025 shares of company stock worth $27,310,113.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Toronto Dominion Bank bought a new position in shares of Tilray during the fourth quarter worth $27,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Tilray in the 4th quarter valued at $71,000. Bronfman E.L. Rothschild L.P. lifted its position in Tilray by 7,266.7% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 1,105 shares of the company’s stock valued at $78,000 after acquiring an additional 1,090 shares in the last quarter. Captrust Financial Advisors bought a new stake in Tilray in the 3rd quarter valued at $103,000. Finally, IFP Advisors Inc lifted its position in Tilray by 61.0% in the 4th quarter. IFP Advisors Inc now owns 1,729 shares of the company’s stock valued at $130,000 after acquiring an additional 655 shares in the last quarter. 7.91% of the stock is currently owned by institutional investors.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
See Also: Yield Curve
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.